Elicio Therapeutics announced a $15 million registered direct offering of 4,380,313 common shares at $3.43 per share, expected to close on July 6, 2026. The company entered a Securities Purchase Agreement with institutional investors and a separate Placement Agency Agreement appointing Titan Partners Group as lead placement agent and B. Riley Securities as co-placement agent. Elicio agreed to pay customary fees and expenses and to a 30-day post-closing restriction on additional equity issuances, enhancing near-term liquidity for operations and programs.
Agreement 1: Elicio Therapeutics Prices $15 Million Registered Direct Offering at $3.43
- Agreement type: Securities Purchase Agreement for registered direct offering of common stock
- Counterparty: Institutional investors
- Signed / Effective: Jul 01 2026 / same
- Duration / Termination: At will
- Reason: Raise capital to fund operations and programs
Agreement 2: Elicio Therapeutics Engages Titan Partners and B. Riley as Placement Agents for Offering
- Agreement type: Placement Agency Agreement for registered direct offering
- Counterparty: Titan Partners Group and B. Riley Securities
- Signed / Effective: Jul 01 2026 / same
- Duration / Termination: At will
- Reason: Engage agents to place offering shares
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.